Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q2

4574.TEDINET S100OZLM
Period2022-01-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.9bn2022-01-01 → 2022-06-30Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥5.1bn2021-01-01 → 2021-06-30Cons.Net sales
Operating income−¥2.4bn2022-01-01 → 2022-06-30Cons.Operating income
Operating income−¥2.3bn2021-01-01 → 2021-06-30Cons.Operating income
Ordinary income−¥2.5bn2022-01-01 → 2022-06-30Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.7bn2021-01-01 → 2021-06-30Cons.Ordinary income
Profit before tax−¥2.8bn2022-01-01 → 2022-06-30Cons.Income before income taxes
Profit before tax−¥2.9bn2021-01-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.4bn2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss
Net income−¥2.4bn2021-01-01 → 2021-06-30Cons.Profit loss
Total assets¥17.4bnat 2022-06-30Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥27.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥7.2bnat 2022-06-30Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥10.2bnat 2022-06-30Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥20.0bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥4.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
Cash & equivalents¥4.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.7bnat 2021-06-30Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2020-12-31dCons.Cash and cash equivalents
Operating cash flow−¥631m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.3bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥96m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.1bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥501m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥4.0bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.3bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-64.172022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.052022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-54.622021-01-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-51.112021-04-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio58.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2022-01-01 → 2022-06-30¥4m
Otherother segmentsrevenue external2022-01-01 → 2022-06-30¥4m
Otherother segmentssegment profit2022-01-01 → 2022-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥645m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.6bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥1.8bn
Otherother segmentsrevenue2021-01-01 → 2021-06-30¥3m
Otherother segmentsrevenue external2021-01-01 → 2021-06-30¥3m
Otherother segmentssegment profit2021-01-01 → 2021-06-30−¥12m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-06-30−¥723m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-06-30¥3.1bn
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-06-30¥3.1bn
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-06-30−¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-06-30¥2.0bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-06-30¥2.0bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-06-30¥594m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-06-30−¥1.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 517
ItemContextValueUnit
Payroll and allowances sgaCurrentYTDDuration538000000JPY
Provision for bonuses sgaPrior1YTDDuration57000000JPY
Provision for bonuses sgaCurrentYTDDuration7000000JPY
Retirement benefit expenses sgaPrior1YTDDuration41000000JPY
Retirement benefit expenses sgaCurrentYTDDuration38000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember1962000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember3140000000JPY
Revenues from external customersPrior1YTDDuration_OtherReportableSegmentsMember3000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5106000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration5106000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_OtherReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember1962000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember3140000000JPY
Net salesPrior1YTDDuration_OtherReportableSegmentsMember3000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5106000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration5106000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember594000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember-2139000000JPY
Operating incomePrior1YTDDuration_OtherReportableSegmentsMember-12000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember-1557000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-723000000JPY
Operating incomePrior1YTDDuration-2280000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember1488000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember365000000JPY
Revenues from external customersCurrentYTDDuration_OtherReportableSegmentsMember4000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1857000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration1857000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_OtherReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember1488000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember365000000JPY
Net salesCurrentYTDDuration_OtherReportableSegmentsMember4000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1857000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration1857000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember-117000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember-1643000000JPY
Operating incomeCurrentYTDDuration_OtherReportableSegmentsMember-11000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass